Antitubercular activity of garlic (allium sativum) extract on combination with conventional antitubercular drugs in tubercular lymphadenitis

Based on our demonstration earlier that ethanol extract, water extract and a compound purified from garlic possessedin vitro antitubercular activity against drug resistant and susceptibleMycobacterium tuberculosis, we tried the effect of garlic extract in 30 patients of tubercular lymphadenitis. For ethical considerations, two groups of patients, 30 each, were given antitubercular therapy (ATT) consisting of isoniazid, rifampicin, ethambutol and pyrazinamide for 30 days. For the next 15 days (31 to 45 days) group 1 patients received 3–6 garlic pearls per day in addition to ATT while group 2 patients received ATT only. From 46th day onwards both the groups received ATT only for 6–8 months. Antitubercular activity of the serum samples collected on 45th day was assessed by its effect on the growth ofM. tuberculois. The serum of group 1 patients showed significantly much higher antitubercular activity than that of group 2 patients. Further, there was relief of dyspeptic symptoms caused by ATT therapy in patients of group 1 with garlic plus ATT therapy but no change in group 2 patients with ATT only. Liver function and hematological tests were normal in both the groups after 6 months of therapy. Garlic extracts or compounds have a good potential as antitubercular(s) drug if given as a supplement to ATT.     

1例应用阿瓦斯丁化疗的观察与护理

目的:探讨应用阿瓦斯丁全身化疗的观察与护理。方法:1例左上肺癌晚期患者伴2型糖尿病,在应用阿瓦斯丁过程中,药液采用生理盐水现配现用,微泵控制输液速度,300 mg药液于90 min内输注完毕,心电监护患者生命体征,随时倾听患者的主诉,做好心理护理。结果:患者使用阿瓦斯丁后未出现过敏反应,无严重高血压及出血,生命体征稳定。结论:严格执行操作规程,严密观察病情变化,做好心理护理,能减少应用阿瓦斯丁的副作用,提高工作效率,保证治疗效果。     

诱导化疗、肿瘤细胞减灭术及术中高温胸腔灌注疗法治疗ⅣA期胸腺瘤

目的研究诱导化疗,肿瘤细胞减灭术及术中高温胸腔灌注疗法对ⅣA期胸腺瘤的治疗效果。方法回顾性研究三年间在完成诱导化疗后行手术治疗的ⅣA期胸腺瘤患者的临床资料。结果没有院内死亡病例。中位随访时间为18.8个月（范围在1.5～31.9个月）。1名患者在术后14个月死于急性心血管意外。剩余存活的4名患者没有复发的证据。结论对于ⅣA期胸腺瘤来说,包括诱导化疗及肿瘤细胞减灭术的综合治疗是安全可行的,充分的胸膜部分切除术是胸膜外肺切除术（EPP）以外的又一选择。     

食道癌术后化疗患者健康相关行为调查及护理对策

目的：探讨食道癌术后化疗患健康相关行为对治疗的意义。方法：对47例食道癌术后化疗患采用问卷调查法进行知、信、行三个方面的调查，并进行统计学处理。结果：90％以上的患相信化疗的效果，74．5％的患确信营养支持的重要性，63．8％的患相信精神心理支持对化疗药效的促进作用，78．7％患不能定期复查。结论：努力使患了解尽可能多的与疾病相关知识，突出重点教育内容和形式，注意个体化教育，提高护理人员临床健康教育能力。     

甲地孕酮提高肿瘤病人化疗期间耐受性的临床观察

从2003年-2007年,将同期入院的69例晚期癌症患者随机分为联合宜利治组及化疗组,观察食欲改善情况、恶心呕吐反应及KPS评分指标。联合组食欲有反应84.3%（27/32）,而对照组59.5%（22/37）,组间比较差异有显著性（P〈0.01）。联合组恶心呕吐无反应68.7%（22/32）,对照组47.5%（17/37）,组间比较差异有显著性（P〈0.01）;KPS评分增加10分56.2%（18/32）,对照组18.9%（7/37）,组间比较差异有显著性（P〈0.01）。甲地孕酮提高恶性肿瘤患者化疗期的耐受性有较好疗效。     

Ferrimagnetic mPEG-b-PHEP copolymer micelles loaded with iron oxide nanocubes and emodin for enhanced magnetic hyperthermia–chemotherapy

As a non-invasive therapeutic method without penetration-depth limitation, magnetic hyperthermia therapy (MHT) under alternating magnetic field (AMF) is a clinically promising thermal therapy. However, the poor heating conversion efficiency and lack of stimulus–response obstruct the clinical application of magnetofluid-mediated MHT. Here, we develop a ferrimagnetic polyethylene glycol-poly(2-hexoxy-2-oxo-1,3,2-dioxaphospholane) (mPEG-b-PHEP) copolymer micelle loaded with hydrophobic iron oxide nanocubes and emodin (denoted as EMM). Besides an enhanced magnetic resonance (MR) contrast ability (r₂ = 271 mM⁻¹ s⁻¹) due to the high magnetization, the specific absorption rate (2518 W/g at 35 kA/m) and intrinsic loss power (6.5 nHm²/kg) of EMM are dozens of times higher than the clinically available iron oxide nanoagents (Feridex and Resovist), indicating the high heating conversion efficiency. Furthermore, this composite micelle with a flowable core exhibits a rapid response to magnetic hyperthermia, leading to an AMF-activated supersensitive drug release. With the high magnetic response, thermal sensitivity and magnetic targeting, this supersensitive ferrimagnetic nanocomposite realizes an above 70% tumor cell killing effect at an extremely low dosage (10 μg Fe/mL), and the tumors on mice are completely eliminated after the combined MHT–chemotherapy.     

奥沙利铂联合LF方案治疗大肠癌临床观察

文章通过临床观察奥沙利铂联合LF方案治疗大肠癌的疗效及毒副反应,治疗有效率57.14%,主要毒副反应为胃肠道反应,骨髓抑制。结果表明该治疗方案治疗大肠癌疗效肯定,耐药性良好,是一种较理想的联合化疗方案。